Jean F. Holloway Sells 18,020 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 18,020 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total value of $425,452.20. Following the sale, the senior vice president now directly owns 197,184 shares in the company, valued at $4,655,514.24. The trade was a 8.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Artivion Stock Down 0.1 %

Shares of NYSE:AORT opened at $23.46 on Friday. Artivion, Inc. has a 1 year low of $19.11 and a 1 year high of $32.33. The business has a 50 day simple moving average of $28.74 and a two-hundred day simple moving average of $27.74. The firm has a market capitalization of $986.28 million, a PE ratio of -1,172.80 and a beta of 1.79. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Artivion (NYSE:AORT) last announced its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $97.31 million for the quarter, compared to analysts’ expectations of $100.82 million. On average, equities analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AORT. JMP Securities reissued a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Stifel Nicolaus reduced their price objective on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Finally, Needham & Company LLC reduced their price objective on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artivion currently has an average rating of “Buy” and a consensus target price of $31.40.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of AORT. Wasatch Advisors LP boosted its position in shares of Artivion by 27.7% during the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company’s stock valued at $29,791,000 after buying an additional 226,160 shares during the period. Lord Abbett & CO. LLC purchased a new stake in shares of Artivion in the third quarter valued at approximately $5,798,000. Point72 Asset Management L.P. purchased a new stake in shares of Artivion in the fourth quarter valued at approximately $5,573,000. First Trust Advisors LP purchased a new stake in shares of Artivion in the fourth quarter valued at approximately $4,771,000. Finally, Tidal Investments LLC boosted its holdings in shares of Artivion by 602.2% in the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock valued at $4,179,000 after purchasing an additional 134,642 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.